504 related articles for article (PubMed ID: 25660193)
1. FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson's disease.
Van der Perren A; Macchi F; Toelen J; Carlon MS; Maris M; de Loor H; Kuypers DR; Gijsbers R; Van den Haute C; Debyser Z; Baekelandt V
Neurobiol Aging; 2015 Mar; 36(3):1559-68. PubMed ID: 25660193
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
[TBL] [Abstract][Full Text] [Related]
3. Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair.
Vivekanantham S; Shah S; Dewji R; Dewji A; Khatri C; Ologunde R
Int J Neurosci; 2015; 125(10):717-25. PubMed ID: 25364880
[TBL] [Abstract][Full Text] [Related]
4. Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated α-synuclein mouse model of Parkinson's disease.
Rauschenberger L; Behnke J; Grotemeyer A; Knorr S; Volkmann J; Ip CW
Neurobiol Dis; 2022 Sep; 171():105798. PubMed ID: 35750147
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors.
Van der Perren A; Toelen J; Casteels C; Macchi F; Van Rompuy AS; Sarre S; Casadei N; Nuber S; Himmelreich U; Osorio Garcia MI; Michotte Y; D'Hooge R; Bormans G; Van Laere K; Gijsbers R; Van den Haute C; Debyser Z; Baekelandt V
Neurobiol Aging; 2015 Mar; 36(3):1543-58. PubMed ID: 25599874
[TBL] [Abstract][Full Text] [Related]
6. Lycopodium Attenuates Loss of Dopaminergic Neurons by Suppressing Oxidative Stress and Neuroinflammation in a Rat Model of Parkinson's Disease.
Jayaraj RL; Beiram R; Azimullah S; Meeran MFN; Ojha SK; Adem A; Jalal FY
Molecules; 2019 Jun; 24(11):. PubMed ID: 31185705
[TBL] [Abstract][Full Text] [Related]
7. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
Coune PG; Bensadoun JC; Aebischer P; Schneider BL
J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
[TBL] [Abstract][Full Text] [Related]
8. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
9. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
10. α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease.
Harischandra DS; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
Toxicol Sci; 2015 Feb; 143(2):454-68. PubMed ID: 25416158
[TBL] [Abstract][Full Text] [Related]
11. Extracellular α-synuclein--a possible initiator of inflammation in Parkinson's disease.
Ren WQ; Tian ZM; Yin F; Sun JZ; Zhang JN
Pharmazie; 2016 Feb; 71(2):51-5. PubMed ID: 27004367
[TBL] [Abstract][Full Text] [Related]
12. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
[TBL] [Abstract][Full Text] [Related]
13. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
15. Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease.
Pradhan S; Andreasson K
Exp Neurol; 2013 Mar; 241():148-55. PubMed ID: 23261765
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
17. α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease.
Lastres-Becker I; Ulusoy A; Innamorato NG; Sahin G; Rábano A; Kirik D; Cuadrado A
Hum Mol Genet; 2012 Jul; 21(14):3173-92. PubMed ID: 22513881
[TBL] [Abstract][Full Text] [Related]
18. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.
He Q; Koprich JB; Wang Y; Yu WB; Xiao BG; Brotchie JM; Wang J
Mol Neurobiol; 2016 May; 53(4):2258-68. PubMed ID: 25972237
[TBL] [Abstract][Full Text] [Related]
19. Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson's disease.
Grotemeyer A; Fischer JF; Koprich JB; Brotchie JM; Blum R; Volkmann J; Ip CW
J Neuroinflammation; 2023 Mar; 20(1):79. PubMed ID: 36945016
[TBL] [Abstract][Full Text] [Related]
20. Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease.
Ulusoy A; Decressac M; Kirik D; Björklund A
Prog Brain Res; 2010; 184():89-111. PubMed ID: 20887871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]